Craig Parker
Chief Executive Officer chez SURROZEN, INC.
Fortune : 23 157 $ au 31/03/2024
Postes actifs de Craig Parker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01/04/2018 | - |
| Chief Executive Officer | 01/03/2018 | - | |
| President | 01/03/2018 | - | |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 04/04/2018 | - |
| Chief Executive Officer | 04/04/2018 | - | |
| President | 04/04/2018 | - | |
| University of Michigan | Chairman | - | - |
| Director/Board Member | 01/01/2005 | - |
Historique de carrière de Craig Parker
Anciens postes connus de Craig Parker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VTV THERAPEUTICS INC. | Director/Board Member | 01/07/2015 | 01/02/2019 |
| Independent Dir/Board Member | 01/07/2015 | 01/02/2019 | |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/08/2014 | 01/03/2018 |
| GERON CORPORATION | Chief Tech/Sci/R&D Officer | 17/02/2014 | 31/07/2014 |
| Corporate Officer/Principal | 03/12/2012 | 17/02/2014 | |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Director of Finance/CFO | 26/06/2009 | 26/11/2013 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 09/08/2011 | 03/08/2012 |
| Vega Therapeutics, Inc. | Chief Executive Officer | 01/01/2009 | 01/01/2011 |
| Founder | 01/01/2009 | 01/01/2011 | |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Craig Parker
| The University of Chicago | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
| Stephen M. Ross School of Business | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 14 |
| Irlande | 2 |
Opérationnelle
| Director/Board Member | 5 |
| Corporate Officer/Principal | 4 |
| Chief Executive Officer | 3 |
Sectorielle
| Health Technology | 10 |
| Consumer Services | 4 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GERON CORPORATION | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| VTV THERAPEUTICS INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Gryphon Therapeutics, Inc.
 Gryphon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gryphon Therapeutics, Inc. develops and produces protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols, such as molecules to create potent medications. Gryphon Therapeutics was founded in 1993 and is headquartered in South San Francisco, CA | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
| Vega Therapeutics, Inc. |
- Bourse
- Insiders
- Craig Parker
- Expérience
